Latest News and Press Releases
Want to stay updated on the latest news?
-
WASHINGTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) has sent more than 640 doses of its investigational cAd3-Marburg Vaccine to Ethiopia to support the country’s...
-
The Global Virus Network issued a statement newly confirmed outbreak of Marburg virus disease in southern Ethiopia.
-
CARLSBAD, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- True Diagnostics, Inc. announced today that it has been awarded a Project Award through the Rapid Response Partnership Vehicle (RRPV) to advance...
-
WASHINGTON, April 16, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to...
-
Photo caption: Rwanda Minister of State for Health, Yvan Butera, was among those who received Sabin’s investigational vaccine in the open-label clinical trial. WASHINGTON, Oct. 31, 2024 (GLOBE...
-
[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024. WASHINGTON, Oct. 05, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has provided...
-
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Virologist and vaccine development leader Kelly Warfield has...
-
WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers...
-
Plasmide sind ein zentrales Ausgangsmaterial für die Herstellung von mRNA- und zellbasierten MedikamentenBioNTech stellt mit unternehmenseigener Plasmid-Herstellungsstätte die Produktion von zentralem...
-
Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugsThe new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in...